Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.33 |
| ▸ | CFD | P00746 | 4/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | BRS3 | P32247 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1301031 | 1.00 | METTL3 (0.64) | METTL3TSHRHIF1ANOTUMCXCR2 | |
| SCHEMBL13771387 | 0.89 | METTL3 (0.53) | METTL3TSHRHIF1ANOTUMCFD | |
| SCHEMBL12108134 | 0.88 | METTL3 (0.48) | METTL3TSHRHIF1ACHRM1BRS3 | |
| SCHEMBL1300751 | 0.87 | METTL3 (0.63) | METTL3NOTUMCXCR2CFDGRIN2B | |
| SCHEMBL1300777 | 0.87 | METTL3 (0.65) | METTL3TSHRHIF1ANOTUMCXCR2 | |
| SCHEMBL1300764 | 0.87 | METTL3 (0.65) | METTL3TSHRHIF1ANOTUMCXCR2 | |
| SCHEMBL1301518 | 0.87 | METTL3 (0.51) | METTL3 | |
| SCHEMBL12108084 | 0.86 | METTL3 (0.69) | METTL3TSHRHIF1ANOTUMCXCR2 | |
| SCHEMBL1045282 | 0.86 | METTL3 (0.73) | METTL3NOTUMCFDCHRM1 | |
| SCHEMBL1045281 | 0.86 | METTL3 (0.73) | METTL3NOTUMCFDCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | ARDEA BIOSCIENCES, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | AARDEA BIOSCIENCES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166123-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885TSHR 4868/4885HIF1A 3992/4885 |
| US-20110269741-A1 | NOVEL COMPOSITIONS AND METHODS OF USE | TYMP, SAMHD1, PNP | METTL3 2709/4885TSHR 4868/4885HIF1A 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.